The Growing Concern of Hepatitis B Reactivation with HIV Treatment Interruptions
For individuals living with both HIV and Hepatitis B (HBV) co-infection, advancements in long-acting antiretroviral therapy (ART) offer promising new treatment avenues. However, a critical area of concern is emerging: the risk of HBV reactivation when ART, specifically tenofovir-based regimens, is interrupted. Recent research highlights the need for vigilant monitoring and a cautious approach to treatment pauses.
Understanding the Reactivation Risk
HBV reactivation occurs when the virus, previously suppressed by antiviral treatment, begins to replicate again. Here’s particularly relevant for those with HIV/HBV co-infection because HIV accelerates liver disease progression. A recent cohort study analyzing over 5,300 individuals with HIV and HBV found that tenofovir interruptions were common. The study, led by Douglas T. Dieterich, Laurence Brunet, and Gerald Pierone Jr., categorized patients based on their reactivation risk: high (HBsAg+), moderate (HBsAg-/HBcAb+/HBsAb negative), and low (HBsAg-/HBcAb+/HBsAb+).
The findings revealed a clear correlation between risk level and reactivation rates. High-risk individuals experienced a reactivation rate of 9.59 per 100 person-years, significantly higher than the 0.58 per 100 person-years observed in the moderate-risk group and 0.04 per 100 person-years in the low-risk group. While the incidence of reactivation *with* hepatitis flare was lower, especially in the high-risk group (3.06 per 100 person-years), the potential for liver damage remains a serious concern.
Suboptimal Monitoring Practices
A key challenge identified in the research is the suboptimal frequency of HBV monitoring during tenofovir interruptions. While ALT testing was routinely performed, HBV DNA and HBsAg testing were less common, particularly in moderate and low-risk groups (8%/31% and 5%/28% respectively for HBV DNA/HBsAg testing). This lack of comprehensive monitoring suggests that some reactivations may be going undetected.
Pro Tip: Regular HBV DNA and HBsAg testing, alongside ALT monitoring, is crucial during any tenofovir interruption to ensure early detection and management of potential reactivation.
The Role of Long-Acting ART and Future Trends
The advent of long-acting ART presents both opportunities and challenges in the context of HBV reactivation. While these therapies can improve adherence and quality of life, interruptions may still occur for various reasons, including drug supply issues or patient preference. The need for robust monitoring protocols becomes even more critical with long-acting ART, as interruptions may be less frequent but potentially more impactful.
Researchers like Laurence Brunet of Epividian are actively working to better understand these risks and develop strategies for mitigating them. Future trends will likely focus on:
- Improved risk stratification tools to accurately identify individuals at higher risk of reactivation.
- Development of more sensitive and rapid HBV monitoring assays.
- Optimized guidelines for managing tenofovir interruptions in HIV/HBV co-infected individuals.
- Exploring alternative strategies to minimize the need for tenofovir interruptions.
Did you know?
HBV reactivation can occur even in individuals with seemingly suppressed HBV, highlighting the importance of ongoing monitoring even after achieving viral suppression.
FAQ
Q: What is HBV reactivation?
A: HBV reactivation is the resumption of HBV replication after it has been suppressed by antiviral treatment.
Q: Who is at highest risk of HBV reactivation during tenofovir interruption?
A: Individuals who are HBsAg positive (high risk) are at the highest risk.
Q: How often should HBV monitoring be performed during tenofovir interruption?
A: HBV DNA and HBsAg testing, in addition to ALT monitoring, should be performed regularly, with frequency determined by individual risk factors.
Q: What are the potential consequences of untreated HBV reactivation?
A: Untreated reactivation can lead to liver inflammation, liver damage, and potentially liver failure.
To learn more about HIV and HBV co-infection, visit NATAP.
Have questions about managing your HIV and HBV co-infection? Share your thoughts in the comments below!
Keep reading